You are here

Bombardier VP Joins TRIUMF Board

14 January 2013

News Release | For Immediate Release | January 14, 2013, 6:00 a.m. PST

BOMBARDIER’S SYLVAIN LÉVESQUE JOINS TRIUMF BOARD

(Vancouver, BC) --- Dr. Sylvain Lévesque, Vice-President of Corporate Strategy at Bombardier Inc., a world-leading manufacturer of innovative transportation solutions, has joined the Board of Management for TRIUMF, Canada’s national laboratory for particle and nuclear physics, for a three-year term.  Owned and operated by a consortium of 17 Canadian universities with core operating funds administered via a contribution agreement through National Research Council Canada, TRIUMF is guided by a Board that includes university vice-presidents of research, prestigious scientists, and leading members of Canada’s private sector.

Paul Young, Chair of TRIUMF’s Board and Vice President, Research at the University of Toronto, said, “We welcome the participation of Sylvain and his extensive experience at Bombardier.  TRIUMF is a national resource for basic research and yet we also fulfill a technological innovation mission for Canada.  Dr. Lévesque will be a valuable addition to the Board.”

Dr. Sylvain Lévesque earned his Ph.D. from MIT in Engineering and worked at McKinsey & Company before joining Bombardier in 1999.  He brings deep experience with large, technical organizations and a passion for science and engineering.  He said, “I am excited to work more closely with TRIUMF.  It has a track record of excellence and I am eager to provide guidance on where Canada’s industrial sector might draw greater strength from the laboratory.

TRIUMF’s Board of Management reflects the unique status of TRIUMF, a laboratory operating for more than forty years as a joint venture from Canada’s leading research universities.  The consortium includes universities from Halifax to Victoria. 

Nigel S. Lockyer, Director of TRIUMF, said, “TRIUMF has always had a dual mission of research and innovation. One of the chief thrusts of our present strategy is advancing isotopes for science and medicine in addition to probing the structure and origins of matter.  I am delighted to work with Dr. Lévesque and expect him to both challenge and expand our business focus in working with industrial partners.”

Dr. Lévesque will attend the next meeting of the Board of Management scheduled for Spring 2013 in Vancouver.